HIGHLIGHTS
SUMMARY
In a chronic neuroinflammatory disease, such as multiple_sclerosis, an MMP9 increase was found in patients` sera and plasma during relapse and during methylprednisolone treatment. Despite this robust evidence in multiple_sclerosis, modifications of MMPs` plasmatic levels at baseline and/or in response to pharmacological or non-pharmacological therapeutic approaches, including NIBS techniques, have not been still explored in AD/MCI. There are several reports regarding the important role of MMP9 in maintaining longterm potentiation (LTP), the major model of synaptic plasticity, both in brain slices and in_vivo in different brain structures that were subjected to . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.